Publications by the researcher in collaboration with EVA DE LAGO FEMIA (15)

2024

  1. Gamificación en farmacología: Escape room virtual

    III Jornada «Aprendizaje Eficaz con TIC en la UCM» (Ediciones Complutense), pp. 101-114

2018

  1. Ingroducción a la farmacología del sistema nervioso central: neurotransmisores, receptores y otros elementos sinápticos

    Velázquez. Farmacología básica y clínica (Editorial Médica Panamericana), pp. 179-208

2015

  1. Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders

    Journal of Neuroimmune Pharmacology, Vol. 10, Núm. 2, pp. 233-244

2012

  1. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects

    Neuropharmacology, Vol. 62, Núm. 7, pp. 2299-2308

2009

  1. Relación del sistema cannabinoide con la fisiopatología y el tratamiento de la esquizofrenia

    Actualización sobre el potencial terapéutico de los cannabinoides (Sociedad Española de Investigación en Cannabinoides (SEIC)), pp. 239-256

2007

  1. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties

    Brain Research, Vol. 1134, Núm. 1, pp. 162-170

  2. Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions

    Life Sciences, Vol. 80, Núm. 10, pp. 979-988

2006

  1. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders

    European Neuropsychopharmacology, Vol. 16, Núm. 1, pp. 7-18

2005

  1. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease

    Brain Research, Vol. 1050, Núm. 1-2, pp. 210-216

  2. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis

    Neurobiology of Disease, Vol. 20, Núm. 2, pp. 207-217

2004

  1. Involvement of the endocannabinoid system in motor disorders

    Current Medicinal Chemistry - Central Nervous System Agents, Vol. 4, Núm. 3, pp. 175-182

  2. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence

    Brain Research, Vol. 1007, Núm. 1-2, pp. 152-159

2003

  1. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors

    European Journal of Medicinal Chemistry

  2. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase

    Journal of Medicinal Chemistry, Vol. 46, Núm. 8, pp. 1512-1522

2002

  1. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide

    European Journal of Pharmacology, Vol. 449, Núm. 1-2, pp. 99-103